BioSpace News Archive

Gilgamesh Pharma, a cutting-edge clinical-stage biotechnology company proudly announces the successful completion of its Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials for GM-1020, the only novel oral, small-molecule NMDA receptor channel blocker currently in clinical development.

Rockwell Medical, Inc. today announced that the Company entered into an amended and restated products purchase agreement with its largest customer (the “Customer”).

AdMeTech Foundation is hosting the 7th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer. This virtual event will take place on September 21-23, 2023.

Outlook Therapeutics, Inc. today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference being held in New York, NY on Tuesday, September 26, 2023 at 1:35 PM ET.

IntelGenx Corp. announced that it has received the first purchase order for RIZAFILM®1 from its commercial partner in the United States, Gensco Pharma.

Hepion Pharmaceuticals, Inc. announced results from a study with in which the anti-cancer activity of Hepion’s lead drug candidate, rencofilstat, was tested in a high through-put screen on 850 cancer cell lines spanning 28 types of cancer at the PRISM lab at the Broad Institute of MIT and Harvard.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s investigational contraceptive DARE-LARC1.

NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, reported financial results for the second quarter ended June 30, 2023.

Lynk Pharmaceuticals Co., Ltd. today announced the successful completion of Series C2 financing.

Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA ® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection.